How to Get Evenity (Romosozumab) in Wisconsin

What Is Romosozumab and Why Does It Matter for Bone Health?

Romosozumab is a monoclonal antibody that inhibits sclerostin, a protein produced by osteocytes that suppresses bone formation. By blocking sclerostin, romosozumab both stimulates new bone growth and reduces bone resorption, a dual mechanism no other osteoporosis drug replicates. The FDA approved Evenity in April 2019 for postmenopausal women with osteoporosis at high risk of fracture, or those who have failed or are intolerant to other therapies (FDA label).

In the landmark ARCH trial (N=4,093), romosozumab reduced new vertebral fractures by 48% compared to alendronate at 24 months [1]. Bone mineral density (BMD) at the lumbar spine increased by 13.7% with romosozumab at 12 months versus 5.0% with alendronate, per the same study published in the New England Journal of Medicine (Saag et al., 2017). These gains make romosozumab a first-line consideration for patients with very low T-scores or recent fragility fractures.

Wisconsin has no state-level restrictions that block access to Evenity beyond standard federal prescribing requirements. The combination of telehealth authorization, Medicaid coverage with prior authorization, and active specialty pharmacy networks means that patients in both Milwaukee and rural Burnett County can access this drug through similar pathways.

Who Can Prescribe Evenity in Wisconsin?

Any licensed physician (MD or DO) in Wisconsin can prescribe Evenity. Nurse practitioners and physician assistants can also prescribe it, provided they hold an active Wisconsin prescriptive authority and operate within their collaborative or supervisory agreements. Wisconsin's scope-of-practice laws grant NPs full practice authority after completing 3 to 500 hours of clinical practice under a collaborative agreement, per Wisconsin Statute 441.16.

In practice, most romosozumab prescriptions originate from endocrinologists, rheumatologists, or orthopedic specialists who manage patients with severe osteoporosis. Primary care providers can prescribe it too, though many prefer to refer complex osteoporosis cases to a specialist for the initial treatment decision and then co-manage follow-up.

The American Association of Clinical Endocrinology (AACE) 2020 guidelines recommend romosozumab as initial therapy for patients at "very high" fracture risk, defined as a T-score of -3.0 or below, a recent fragility fracture within the past 12 months, or fractures while on approved osteoporosis therapy (AACE 2020 Guidelines). Dr. Pauline Camacho, lead author of the AACE guidelines, stated: "For patients at very high fracture risk, beginning with an anabolic agent like romosozumab followed by an antiresorptive offers the greatest fracture risk reduction."

Using Telehealth to Get an Evenity Prescription in Wisconsin

Wisconsin permits telehealth prescribing for romosozumab. The state's telehealth parity law (Wisconsin Act 56, signed in 2020) requires insurers to cover telehealth visits at the same rate as in-person visits, which removes a financial barrier that once discouraged remote consultations for specialty medications.

A telehealth visit for Evenity typically involves the following steps. First, the provider reviews your medical history, DEXA scan results, and fracture history. Second, they order pre-treatment labs (discussed below). Third, if you meet clinical criteria, they submit a prescription to a specialty pharmacy, along with prior authorization paperwork to your insurer.

Telehealth is particularly valuable for patients in northern and western Wisconsin, where endocrinology practices may be an hour or more away. The initial consultation can happen over video. Injections, however, must be administered in person or taught for self-injection. Each Evenity dose consists of two prefilled syringes (105 mg each), injected subcutaneously in the abdomen, thigh, or upper arm. Some patients self-administer at home after training; others visit a clinic or infusion center monthly.

The Endocrine Society's 2020 clinical practice guideline notes that patients receiving romosozumab should be transitioned to an antiresorptive agent (such as denosumab or a bisphosphonate) after completing the 12-month course, to maintain BMD gains (Endocrine Society, 2020). Your telehealth provider should outline this transition plan before prescribing.

Lab Requirements Before Starting Romosozumab in Wisconsin

Prescribers in Wisconsin follow the same pre-treatment lab panel that the FDA label and specialty pharmacies require nationally. There is no Wisconsin-specific lab mandate, but insurers and pharmacy benefit managers will typically deny prior authorization if key labs are missing.

Standard pre-treatment labs include:

• DEXA scan (dual-energy X-ray absorptiometry): Confirms a T-score consistent with osteoporosis (typically -2.5 or below, or -1.0 to -2.5 with additional risk factors). Results should be dated within the last 24 months.
• 25-hydroxyvitamin D level: The FDA label specifies that hypocalcemia must be corrected before initiating romosozumab. A vitamin D level below 30 ng/mL generally warrants repletion first.
• Serum calcium: Must be within normal range. Romosozumab can lower serum calcium, and starting treatment in a hypocalcemic patient increases the risk of serious adverse events.
• Complete metabolic panel (CMP): Screens kidney and liver function. Severe renal impairment does not require dose adjustment per the label, but it does raise the risk of hypocalcemia and warrants closer monitoring.
• Bone turnover markers (optional but common): Serum CTX (C-terminal telopeptide) and P1NP (procollagen type 1 N-terminal propeptide) help track treatment response. P1NP rises sharply within the first month of romosozumab therapy.

The FRAME trial (N=7,180) demonstrated that romosozumab increased P1NP by approximately 145% above baseline within one month, confirming its rapid anabolic effect on bone formation (Cosman et al., 2016). This is the biomarker most clinicians use to confirm the drug is working.

Wisconsin insurers, including those administering Medicaid, expect to see DEXA, calcium, and vitamin D values documented in the prior authorization submission.

Wisconsin Medicaid and Private Insurance Coverage

Wisconsin Medicaid covers Evenity for severe osteoporosis with prior authorization. The prior authorization process requires documented evidence of:

1. A diagnosis of postmenopausal osteoporosis with a DEXA T-score of -2.5 or lower at the hip or spine, OR a history of fragility fracture.
2. Failure of, intolerance to, or contraindication to at least one first-line antiresorptive therapy (typically alendronate or risedronate). Some plans waive this step-therapy requirement for patients at very high fracture risk.
3. No history of myocardial infarction or stroke within the preceding 12 months (per the FDA black box warning).
4. Pre-treatment lab values showing corrected calcium and adequate vitamin D.

Private insurers in Wisconsin (including plans from Anthem, Quartz, Group Health Cooperative, and Network Health) generally follow similar prior authorization criteria. Turnaround time for PA decisions is typically 5 to 15 business days. If denied, your provider can file a peer-to-peer appeal.

The wholesale acquisition cost (WAC) of Evenity is approximately $1,825 per monthly dose, putting the full 12-month course near $21,900. Amgen offers the Evenity Complete patient support program, which includes copay cards for commercially insured patients (reducing out-of-pocket costs to as low as $5 per dose) and assistance navigating prior authorization.

The ARCH trial's fracture reduction data [1] is the clinical evidence most commonly cited in PA appeals. At 24 months, the romosozumab-to-alendronate sequence reduced clinical fractures by 27% and nonvertebral fractures by 19% compared to alendronate alone (Saag et al., 2017).

Specialty and 503A Pharmacy Access in Wisconsin

Evenity is classified as a specialty medication and is not typically stocked at retail pharmacies like Walgreens or CVS. Instead, it flows through specialty pharmacy channels. Wisconsin has multiple specialty pharmacies that dispense Evenity, including national networks such as Optum Specialty Pharmacy, CVS Specialty, and Accredo (Express Scripts). These pharmacies handle the cold-chain shipping, patient onboarding, and injection training required for this drug.

Licensed 503A compounding pharmacies in Wisconsin can also participate in the dispensing chain, though romosozumab is a biologic and cannot be compounded from raw ingredients. A 503A pharmacy's role here is limited to providing ancillary compounding services (such as custom vitamin D or calcium preparations) rather than compounding the romosozumab itself. The brand-name Evenity prefilled syringe is the only available formulation. No biosimilar exists as of May 2026.

For patients in rural areas, specialty pharmacies ship Evenity directly to the patient's home or to their provider's office in temperature-controlled packaging. Delivery typically takes 3 to 7 business days after the prescription and prior authorization are finalized.

Cardiovascular Safety Considerations

The FDA placed a black box warning on Evenity based on cardiovascular signal data from the ARCH trial. In that study, major adverse cardiac events (MACE) occurred in 2.5% of patients receiving romosozumab versus 1.9% of those receiving alendronate during the first 12-month treatment period (Saag et al., 2017). The absolute difference was small, but the signal was consistent enough to prompt the boxed warning.

Romosozumab should not be initiated in patients who have had a myocardial infarction or stroke within the past year. Prescribers in Wisconsin should assess cardiovascular risk before starting therapy and document this assessment as part of the PA submission. The AACE guidelines recommend weighing the patient's fracture risk against their cardiovascular profile on a case-by-case basis (AACE 2020).

A separate analysis published in the Journal of Bone and Mineral Research evaluated pooled cardiovascular data across all romosozumab trials and found no statistically significant increase in MACE in the FRAME trial or in the phase 2 dose-finding studies (Cummings et al., 2020). The cardiovascular signal appears to be concentrated in the ARCH population, which compared romosozumab to an active comparator (alendronate) rather than placebo.

What Happens After 12 Months of Romosozumab?

Romosozumab is approved for a maximum of 12 monthly doses. This is not a soft recommendation. The sclerostin-blocking effect attenuates over time as anti-drug antibodies develop, and BMD gains begin to reverse within months of discontinuation if no follow-up therapy is started.

The standard protocol is to transition to an antiresorptive agent immediately after the 12th dose. Denosumab (Prolia) is the most common choice because it preserves and extends the BMD gains from romosozumab. In the FRAME extension study, patients who received romosozumab for 12 months followed by denosumab for 12 months achieved total hip BMD gains of 6.9% from baseline at 24 months (Cosman et al., 2018).

Oral bisphosphonates (alendronate, risedronate) are an alternative transition therapy for patients who prefer to avoid injections or who have concerns about denosumab's own rebound risk on discontinuation. Your Wisconsin provider should have a written plan for the post-romosozumab phase before administering the first injection.

Timeline: From First Appointment to First Injection in Wisconsin

A realistic timeline for a Wisconsin patient starting Evenity from scratch:

• Week 1: Initial consultation (in-person or telehealth). Provider orders DEXA scan and labs.
• Weeks 2 to 3: Labs completed. DEXA scan performed (wait times vary; UW Health and Froedtert typically schedule within 1 to 2 weeks).
• Week 3 to 4: Provider reviews results, confirms eligibility, submits prescription and prior authorization.
• Weeks 4 to 6: Prior authorization decision (5 to 15 business days). If denied, peer-to-peer appeal adds 1 to 2 weeks.
• Weeks 5 to 7: Specialty pharmacy ships Evenity. Cold-chain delivery takes 3 to 7 business days.
• Weeks 6 to 8: First injection administered.

Total elapsed time from first appointment to first dose: 6 to 8 weeks in a straightforward case. Delays from insurance denials, lab scheduling, or pharmacy backorders can extend this to 10 to 12 weeks. Patients with recent DEXA scans and labs already on file may compress the timeline to 3 to 4 weeks.